Gilead Sciences (GILD) Tops Q3 EPS by 33c, Updates FY15 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Gilead Sciences (GILD) Tops Q3 EPS by 33c, Updates FY15 Guidance
October 28, 2015 1:47 PM EDT
Maxim Group reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target to $137.00 (from $129.00), following the company's 3Q earnings results. Gilead delivered a very strong quarter well ahead of street estimates. Gilead raised guidance for full year... More
October 28, 2015 8:53 AM EDT
Cowen analyst Phil Nadeau reiterated an Outperform rating and bumped his price target on Gilead Sciences (NASDAQ: GILD) to $130.00 (from $125.00) as HCV sales drove the top and bottom-line and guidance was ralsed.
Nadeau commented, "Gilead reported solid Q3 financials with HCV revenue... More
October 28, 2015 6:25 AM EDT
Oppenheimer analyst Wendy Lam reiterated an Outperform rating and $124 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and raise' Q3.
Lam commented, "GILD reported a healthy 3Q15 beat, with revenue and non-GAAP EPS of $8.30B and $3.22 topping Street consensus estimates of $7.81B and $2.87; GILD... More
